80 results
8-K
EX-99.1
KA
Kineta Inc
24 May 23
Regulation FD Disclosure
9:30am
innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets
8-K
EX-99.6
pj064zk
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
8-K
EX-99.2
0unyjqa
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
424B3
qziv 55oe
10 Nov 22
Prospectus supplement
4:21pm
425
yd4irk9lyu5
29 Aug 22
Business combination disclosure
4:03pm
8-K
EX-99.1
fg3x8t ipmkf
29 Aug 22
Yumanity Therapeutics Announces Filing of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with Kineta
4:01pm
8-K
EX-99.1
e173r0 glaptj
4 Aug 22
Yumanity Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Developments
4:51pm
425
agg9138nis0k
28 Jun 22
Business combination disclosure
4:03pm
8-K
EX-99.1
wwwq6258al1q3kkne3a
28 Jun 22
Kineta Announces Appointment of Thierry Guillaudeux, PhD to Chief Scientific Officer
4:02pm